Emodin anthraquinones inhibited the enzymatic activity ATP-citrate lyase (ACL), a key player in cancer cell metabolism. Lead compound 1d inhibited A549 lung cancer cell proliferation and reduced the stemness of A549 cells. Docking suggested that anthraquinone inhibitors occupied an allosteric site adjacent to the citrate-binding domain of ACL.